Home › Companies › BMEA

Biomea Fusion

BMEA Lead: Phase 2 3 Biotech Distilled articles ↓

Metabolic Small Molecule

Most recent annual filing: 2026-03-24

Pipeline (5 active programs)

icovamenib

BMF-219

Small Molecule Target: menin

Type 2 Diabetes Phase 2 oral
Type 1 Diabetes Phase 2 oral

BMF-650

Small Molecule Target: GLP-1 receptor

Obesity Phase 1 oral

BMF-500

Small Molecule Target: FLT3

Undisclosed indication Phase 1

icovamenib

Small Molecule Target: menin

Obesity Preclinical oral University of Leicester

Biotech Distilled coverage (3)

2026-06-08 UPDATE: Biomea Fusion (BMEA) - The ADA Receipts and the Quiet Catalyst Slip
2026-04-28 UPDATE: Biomea Fusion (BMEA) - The Zombie Trial Wakes Up 🔒 Paid
2026-04-04 Biomea Fusion (BMEA) - Scientific Deep Dive for Icovamenib and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.